Dynavax Technologies Corporation (NASDAQ:DVAX) will be discussing 3Q20 financial results with the investment community.on 5th November 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.dynavax.com
Earnings Expectation
Dynavax Technologies Corporation is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, DVAX to report 3Q20 loss of $ 0.2 per share. For the full year, analysts anticipate top line of $ 35.30 million, while looking forward to loss of $ 1.12 per share bottom line.
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the bodys innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Its product candidates include SD-101, a cancer immunotherapy that is in Phase 2 clinical trials; DV281, an investigational TLR9 agonist, which is in Phase I clinical trial for the treatment of non-small cell lung cancer; and AZD1419, which is in Phase IIa clinical trial to treat asthma.
